United States v. Nazir

211 F. Supp. 2d 1372, 2002 U.S. Dist. LEXIS 13057, 2002 WL 1592499
CourtDistrict Court, S.D. Florida
DecidedJuly 16, 2002
Docket01-1029-CR
StatusPublished
Cited by2 cases

This text of 211 F. Supp. 2d 1372 (United States v. Nazir) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Nazir, 211 F. Supp. 2d 1372, 2002 U.S. Dist. LEXIS 13057, 2002 WL 1592499 (S.D. Fla. 2002).

Opinion

JORDAN, District Judge.

Order Denying Motion to Dismiss Counts 15-24

The defendants move to dismiss counts 15-24 of the indictment on the ground that they fail to allege criminal offenses. For the reasons which follow, the motion to dismiss [D.E. 81] is denied.

I

The indictment alleges that defendant Carlos Nazir, a physician licensed to practice in the state of Florida, wrote “false prescriptions” for prescription drugs (“Power Gel” and “Vigor”) which had not been approved by the FDA, referring to them respectively as “tri-mix” and “bi-mix.” See Indictment at ¶¶ 8, 12-13, 17. Dr. Nazir, according to the indictment, “used the names of patients in his medical practice ... without their knowledge or permission for the prescriptions that were sent” to co-defendants David Gaudio and Prescription Specialties, Inc. “These patients never received the drugs as reflected on the false prescriptions.” See id. at ¶ 18. Instead, Mr. Gaudio and Prescription Specialties filled the false prescriptions, caused bulk shipments of the drugs to be mailed to Dr. Nazir, and simultaneously sent invoices for the false shipments to co-defendants Francisco Munoz, Alberto Liona, and U.S. One Telemarketing, Inc. See id. at ¶ 19. Dr. Nazir then forwarded the drugs to Mr. Munoz, Mr. Liona, and U.S. One Telemarketing' for repackaging and further shipment to “unsuspecting customers throughout the United States.” See id. at ¶ 20. Mr. Munoz, Mr. Liona, and U.S. One Telemarketing caused monies to be paid to Dr. Nazir “in exchange for his role in writing prescriptions.” These monies were “commissions [Dr. Nazir] was to receive from sales of Tower Gel’ and ‘Vigor.’ ” See id. at ¶ 25. Mr. Munoz, Mr. Liona, and U.S. One Telemarketing also caused payments to be made to Dr. Nazir, through International Urological Consultants, “for his role in writing phony prescriptions.” See id. at ¶ 26.

Counts 15-20 charge all of the defendants with the dispensing of prescription drugs without a prescription, and with the intent to defraud or mislead, in violation of 21 U.S.C. §§ 331(a) and 333(a)(2). Each of these counts alleges that on a particular date, “Power Gel” or “Vigor” were dispensed contrary to 21 U.S.C. § 353(b)(1), “in that the drugs were dispensed without the prescription of a practitioner licensed by law to administer them, which resulted in the drugs being misbranded while held for sale.”

Counts 21-24 are similar. These counts charge all of the defendants with the dispensing of prescription drugs (i.e., “Power Gel” or “Vigor”) on certain dates without a valid prescription, and with the intent to defraud or mislead, in violation of 21 U.S.C. §§ 331 (k) and 333(a)(2). The counts allege that the drugs were dispensed contrary tó 21 U.S.C. § 353(b)(1), “in that the drugs were dispensed without *1374 the prescription of a practitioner licensed by law to administer them,” which “resulted in the drugs being misbranded.”

II

Under 21 U.S.C. § 331(a), it is unlawful to “introduc[e] or deliver[] for introduction into interstate commerce ... any ... drug ... that is adulterated or misbranded.” And under § 331(k), it is unlawful to commit any act “while [an] article is held for sale ... after shipment in interstate commerce and [which] results in the article being adulterated or misbranded.” If committed with the “intent to defraud or mislead,” a violation of § 331(a) is punishable by up to three years in prison and a fine of up to $10,000. See 21 U.S.C. § 333(a)(2).

In turn, 21 U.S.C. § 353(b)(1), which was added to the Food, Drug, and Cosmetic Act in 1951, provides in pertinent part as follows:

(b) Prescription by physician....
(1) A drug intended for use by man which—
(A) because of its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, is not safe for use except under the supervision of a practitioner licensed by law to administer such drug;
(B) is limited by an approved application under section 355 of this title to use under the professional supervision of a practitioner licensed by law to administer such drug,
shall be dispensed only (i) upon a mitten prescription of a practitioner licensed by law to administer such drug, or (ii) upon an oral prescription of such practitioner which is reduced promptly to writing and filled by the pharmacist, or (iii) by refilling any such written or oral prescription-The act of dispensing a drug contrary to the provisions of this paragraph shall be deemed to be an act which results in the drug being mis-branded while held for sale.

(emphasis added). As explained in United States v. Carlisle, 234 F.2d 196, 199 (5th Cir.1956), a violation of § 353(b)(1) constitutes misbranding and is punishable under § 331.

Ill

The indictment alleges that Dr. Nazir— with the intent to defraud or mislead— wrote false “Power Gel” and “Vigor” prescriptions for patients of his whom he never evaluated with respect to these drugs, and that the customers who ultimately received the drugs were never examined by, or consulted, a doctor about the drugs. In short, the indictment charges that the defendants used Dr. Nazir’s so-called phony prescriptions as a means for unlawfully delivering the drugs to individuals without the benefit of medical consultations or examinations.

The defendants, invoking the rule of lenity, nevertheless argue that counts 15-24 fail to state criminal offenses because the indictment alleges that Dr. Nazir in fact issued prescriptions for “Power Gel” and “Vigor.” In the defendants’ view, § 353(b)(1) says only that a prescription by a licensed doctor is required, and it makes no difference whether the prescription is phony. If a doctor signs a paper prescribing a drug for someone — no matter what the circumstances — there can be no mis-branding under the statute. The government, on the other hand, asserts that a phony prescription is no prescription at all under § 353(b)(1), and that the so-called prescriptions issued by Dr. Nazir caused the “Power Gel” and “Vigor” to be mis-branded. The critical question, then, is the meaning of the word “prescription” as it is used in the statute. See generally United States v. Plummer,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Peter Bolos
104 F.4th 562 (Sixth Circuit, 2024)

Cite This Page — Counsel Stack

Bluebook (online)
211 F. Supp. 2d 1372, 2002 U.S. Dist. LEXIS 13057, 2002 WL 1592499, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-nazir-flsd-2002.